Information Provided By:
Fly News Breaks for February 13, 2020
Feb 13, 2020 | 12:21 EDT
Piper Sandler analyst Danielle Brill maintained a Neutral rating on Alkermes following the company's Q4 results, saying that with anticipated revenues of over $1B and reduced spend expected in 2020, she is becoming slightly more constructive on the name. However, Brill tells investors in a research note that she still has concerns about the pipeline however, and even though the company has made some progress, she believe additional near-term expansion is needed.
News For ALKS From the Last 2 Days
Mar 1, 2021 | 09:53 EST
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. Atotech (ATC) initiated with a Buy at Deutsche Bank, Jefferies and BofA, initiated with an Overweight at JPMorgan, initiated with an Outperform at Credit Suisse, RBC Capital and BMO Capital. 2. Sensei Biotherapeutics (SNSE) initiated with an Overweight at Piper Sandler, a Buy at Citi and an Outperform at Oppenheimer. 3. Boston Beer (SAM) initiated with an Overweight at Morgan Stanley. 4. Alkermes (ALKS) assumed with a Hold at Jefferies. 5. EyePoint (EYPT) initiated with an Outperform at Cowen. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.